PURE Bioscience Appoints New CEO
Experienced Food Industry Business Leader
SAN DIEGO, CA -- (Marketwired) -- 09/10/13 -- PURE Bioscience, Inc.
(OTCQB: PURE), creator of the patented silver dihydrogen citrate
(SDC) antimicrobial, today announced the appointment of Hank Lambert
as its new Chief Executive Officer. Mr. Lambert replaces the interim
CEO, Dave Pfanzelter, who remains as Chairman of the Board. The
company reported that the management change is part of its previously
announced reorganization establishing new and experienced leadership
focused on commercialization of SDC technology in the food industry
as a unique and proprietary antimicrobial agent to protect consumer
safety against various pathogens.
Mr. Lambert, who will also serve as a company director, is an
accomplished food industry and consumer products executive with broad
management skills, including strategic planning and business
development, go-to-market execution, business integration and food
safety. With over 35 years of industry experience, Mr. Lambert has
established a proven track record of growing both revenues and
earnings at public and private companies such as Heublein Inc., RJ
Reynolds, Nabisco, Inc. and Pinnacle Foods. Mr. Lambert most recently
served as the General Manager, Global Food and Water Businesses, at
UL LLC (Underwriters Laboratories), and has held various business
unit leadership positions servicing the foodservice and leading
consumer food brands markets. Mr. Lambert has also served on boards
and as a member of various food industry associations, including the
International Foodservice Manufacturers Association (IFMA), Institute
of Food Technologists and Safe Supply of Affordable Food Everywhere
"Having spent my career in the food, foodservice and, most recently,
food safety industries, I am well aware of the growing market need
for a proven solution such as PURE's SDC-technology that delivers
superior, broad-spectrum antimicrobial efficacy," said Hank Lambert,
Chief Executive Officer. "I am very excited about the opportunity to
lead and drive customer adoption of PURE's safe and effective product
solutions addressing the ever increasing market requirements for
improved food safety for consumers and the environment."
"We are pleased to recruit a food industry executive of such business
acumen, caliber and accomplishments as Hank Lambert. His reputation
as a goal-driven leader fits our requirements for laser-focused
discipline and experience to drive the future commercial adoption of
our SDC-based products into the food safety marketplace," stated Dave
Pfanzelter, Chairman of the Board of PURE. "This management team is
well positioned to drive to market leadership in delivering new and
effective food safety solutions to our customers in foodservice and
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and markets technology-based
bioscience products that provide solutions to numerous global health
challenges, including Staph (MRSA) and Carbapenem-resistant
Enterobacteriaceae (CRE)/NDM-1+. PURE's proprietary high efficacy/low
toxicity bioscience technologies, including its silver dihydrogen
citrate-based antimicrobials, represent innovative advances in
diverse markets and lead today's global trend toward industry and
consumer use of "green" products while providing competitive
advantages in efficacy and safety. Patented SDC is an
electrolytically generated source of stabilized ionic silver, which
formulates well with other compounds. As a platform technology, SDC
is distinguished from competitors in the marketplace because of its
superior efficacy, reduced toxicity and the inability of bacteria to
form a resistance to it. PURE is headquartered in El Cajon,
California (San Diego metropolitan area). Additional information on
PURE is available at www.purebio.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "expect," "intend," "project" or similar expressions.
These statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's cash
position and liquidity requirements, the Company's failure to
implement or otherwise achieve the benefits of its proposed
initiatives and business plans, acceptance of the Company's current
and future products and services in the marketplace, the ability of
the Company to develop effective new products and receive regulatory
approvals of such products, competitive factors, dependence upon
third-party vendors, and other risks detailed in the Company's
periodic report filings with the Securities and Exchange Commission.
By making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes after
the date of this release.
Tom Hemingway, Redwood Investment Group
Peter C. Wulff, CFO & COO
Pure Bioscience, Inc.
Press spacebar to pause and continue. Press esc to stop.